How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,092 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. A Study to Evaluate OPTI-BIOMEâ„¢ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population

control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives (stable for 1 month) including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s

2016 Clinical Trials

222. Contraceptive Practices of Women With Complex Congenital Heart Disease. (Abstract)

) 84%, intrauterine device (18%), Depo-Provera (15%), vaginal ring (7%), patch (6%), hormonal implant (2%), Plan B (19%), and sterilization (16%). Overall OC use was not significantly different by CHD complexity. Women with CHD of great complexity were more likely to report a thrombotic event while taking OC than those with less complex CHD (9% vs 1%, p = 0.003). Contraception counseling by the ACHD team was noted by 43% of subjects. Unplanned pregnancy was reported by 25% with no statistical

2016 American Journal of Cardiology

223. Pilot Research as Advocacy: The Case of Sayana Press in Kinshasa, Democratic Republic of the Congo Full Text available with Trip Pro

Sayana Press and other contraceptive methods at the community level through medical and nursing students. Sayana Press is similar in formulation to the injectable contraceptive Depo-Provera but contains a lower dose and is administered subcutaneously using a single-use syringe with a short needle called the Uniject system. The Uniject system allows Sayana Press to be administered by community health workers without clinical training or by self-injection. In this pilot, the advocacy objective

2016 Global Health: Science and Practice

224. Long-Acting Reversible Contraception and Condom Use Among Female US High School Students: Implications for Sexually Transmitted Infection Prevention. Full Text available with Trip Pro

compared with users of moderately effective contraceptive methods (ie, oral, Depo-Provera injection, patch, and ring contraceptives).To compare condom use between sexually active female LARC users and users of moderately effective contraceptive methods.Cross-sectional analysis using data from the 2013 national Youth Risk Behavior Survey, a nationally representative sample of US high school students in grades 9 through 12. Descriptive analyses were conducted among sexually active female students (n (...) intercourse. We created an indicator variable to distinguish those reporting use of (1) LARC (intrauterine device or implant), (2) oral contraceptives, and (3) Depo-Provera, patch, or ring.Among the 2288 sexually active female participants (56.7% white; 33.6% in 12th grade), 1.8% used LARC; 5.7% used Depo-Provera, patch, or ring; 22.4% used oral contraceptives; 40.8% used condoms; 11.8% used withdrawal or other method; 15.7% used no contraceptive method; and 1.9% were not sure. In adjusted analyses, LARC

2016 JAMA pediatrics

225. TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest

/implants Norplant®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation. Postmenopausal is defined as having the last menstrual cycle in at least 12 months Negative urine pregnancy test results at the time of study entry (if applicable (...) , nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, contraceptive patches/rings/implants Norplant®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence, or vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active]. Current participation or participation within 30

2016 Clinical Trials

226. A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

kg/m2 and 30 kg/m2, inclusive, and must weigh more than 45 kg Male subjects must either have a vasectomy or agree that they and any female partners will use 2 acceptable forms of contraception, one of which must be a condom, until 30 days after the last dose of study drug. Other acceptable forms of contraception include hormonal contraceptives, intrauterine device, Depo Provera®, Norplant® System Implants, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, and contraceptive sponge

2016 Clinical Trials

227. Exploratory Pharmacodynamic Study of Tenofovir-Based Products

had at least two spontaneous menses since pregnancy outcome Injection of Depo-Provera in the last 10 months or use of other progestin-only based contraceptive (including hormonal IUD) Currently breastfeeding or planning to breastfeed during the course of the study History of sensitivity/allergy to any component of the study products, topical anesthetic, or to both silver nitrate and Monsel's solution In the last three months, diagnosed with or treated for any STI, by self report Positive test

2016 Clinical Trials

228. Exploratory Study for Allergy Relief Onset

during ragweed challenge Symptom Induction Phase of each Treatment Visit; Body Mass Index (BMI) in the range of 18 to 30 kg/m2 Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, injectable contraceptive (e.g. Depo-Provera®), or a double barrier and have a negative pregnancy test at Screening and prior to IMP

2016 Clinical Trials

229. Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment

reliable method of birth control during the trial (e.g., birth control pills, Depo-Provera, and/or condoms with spermicide). Must be clinically stable (i.e., no inpatient hospitalizations for 3 months prior to enrollment, no changes in medication in the four weeks prior to enrollment) Exclusion Criteria: current or past history of cardiovascular disease including myocardial infarction, acute coronary syndrome, angina pectoris, coronary artery disease, atrial fibrillation/flutter, cor pulmonale

2016 Clinical Trials

230. A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults

), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Non-hormonal intrauterine devices Vasectomy of partner BMI 18.5-29.9 kg/m2 (±1 kg/m2) Seated resting systolic blood pressures between 130-150 mmHg (inclusive) and diastolic blood pressure ≤ 100 mmHg at screening visit Agreement to maintain current level of physical activity and diet throughout the study Agrees to comply with study procedures including

2016 Clinical Trials

231. Prebiotic in Preventing Low Birth Weight

unwilling to comply with study protocol (x) Presence of UTI or bacteriuria in a morning mid stream fresh urine sample (xi) Presence of abnormal vaginal flora (Nugent score >7) (xii) History of irregular bleeding due to injectable Depo-Provera Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2016 Clinical Trials

232. A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

) Participants will remain on baseline mood stabilizer pharmacotherapy with lithium during the study. They will need to have been on lithium with stable therapeutic blood levels for at least two weeks prior to randomization and agree not to change medications during the study. Women of child bearing potential must agree to use adequate contraception (e.g. oral contraceptives, intrauterine device, double barrier methods), if sexually active. Depo Provera is acceptable if it is started 3 months prior

2016 Clinical Trials

233. Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

: abstinence, condoms (male or female with or without a spermicide), diaphragm or cervical cap with spermicide, intrauterine device, contraceptive pills or patch, Norplant, Depo-Provera or other FDA approved contraceptive method, or male partner has previously undergone a vasectomy as declared in medical history. EXCLUSION CRITERIA: Any subject who meets any of the following criteria will not qualify for entry into the study: History of prior infection with a filovirus or prior participation in a filovirus

2016 Clinical Trials

234. A Study Investigating the Effects of Niagenâ„¢ in Healthy Adults.

, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Non-hormonal intrauterine devices Vasectomy of partner Healthy as determined by laboratory results, medical history, and physical exam Agrees to comply with study procedure Agrees to maintain current level of physical activity throughout the study and avoid exercising on the day of study visits 3 to 7 (prior

2016 Clinical Trials

235. Effect of Hypoglycemia on Sleep

by the investigator after reviewing the subjects activity level) Current use of an insulin pump. Willingness to follow all study procedures, including attending all clinic visits. Willingness to sign informed consent and HIPAA documents. Exclusion Criteria: Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant

2016 Clinical Trials

236. Pathophysiology of Paget's Disease of Bone

NOT have evidence of Paget's disease of bone as defined by: No bone pain or bony deformity Normal serum alkaline phosphatase Exclusion Criteria: Osteosarcoma or other blastic bony metastases alone Fibrous dysplasia of bone Hyperostosis frontalis interna All men and women < 18 years or > 99 years Pregnancy (women) determined by self-report Current use of oral contraceptive tablets or Depo-Provera™ (women) Current use of hormone replacement therapy Creatinine clearance < 60 ml/min./1.73 m2 by Cockcroft

2016 Clinical Trials

237. An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Use of oral contraceptives in the 30 days preceding screening. Use of Depo-Provera® in the preceding 10 months. Use of GnRHas (e.g. Lupron Depot) within 3 months prior to screening (Lupron Depot must have a wash-out period of 3 months prior to screening) Has an IUD in place Current cervical dysplasia classified as Atypical Squamous Cells of Undetermined Significance (ASCUS) associated with high-risk human papilloma virus (HPV) Current diagnosis of Low/High Grade Squamous Intraepithelial Lesion

2016 Clinical Trials

238. Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

bleeding has diabetes has strong family history of breast cancer (defined as one or more first degree relatives, breast cancer occurring before menopause in three or more family members, regardless of degree of relationship, and any male family member with breast cancer), or current or history of breast cancer, or undiagnosed mass detected by breast exam has current or history of cervical cancer has severe cirrhosis (decompensated) or liver tumors has known significant renal disease used Depo-Provera (...) Contraceptive Injection or Depo-subcutaneous Provera 104 (DMPA) products in the past 12 months used any of the following medications within 1 month prior to enrollment: any investigational drug prohibited drugs per protocol oral contraceptives, contraceptive ring or patch levonorgestrel intrauterine system (LNG IUS) or contraceptive implant used a combined injectable contraceptive in the past 6 months less than 3 months since the end of last pregnancy currently lactating is using or plans to use prohibited

2016 Clinical Trials

239. Omental Islet Transplant

discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. If sexually active, subject must use at least two medically accepted methods of birth control from the following list: oral contraceptives, Norplant®, Depo-Provera®, intrauterine device (IUD), barrier devices with spermicide. Condoms used alone are not acceptable. Instead of the male condom, it is acceptable to use

2016 Clinical Trials

240. Intranasal Oxytocin in Hypothalamic Obesity

, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study. Hypothalamic obesity, defined for the purposes of this protocol as: previously diagnosed with a brain tumor* currently overweight or obese (BMI > 85%ile for age/sex for < 18 years, BMI > 25 kg/m2 for 18 - 21 years) has at least one other endocrinopathy, indicating hypothalamic damage rate of annualized weight gain during any 6 month period (given variability in clinical course) preceding

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>